Effect of Pyridoxine on the Depletion of Tissue Pyridoxal Phosphate by Carbidopa

Luisa Airoldi, Carol J. Watkins, Jane F. Wiggins, and Richard J. Wurtman

One or two hours after rats received a single dose (100 or 800 mg/kg, intraperitoneally) of carbidopa (MK-486; α-methyl-L-dopa hydrazine), pyridoxal-5’-phosphate (PLP) concentrations were significantly depressed in peripheral tissues (serum, liver, and muscle) and in hypothalami, but not in whole brains. Repeated administration of carbidopa (three 100 mg/kg doses per day for 3 days) lowered PLP concentrations in serum, liver, and muscle (by 88%, 51%, and 18%, respectively) among rats killed 2 hr after the final injection. PLP levels in brain and hypothalamus were also reduced significantly (by 22% and 18%, respectively) after this treatment. The activity of aromatic L-amino acid decarboxylase (AAAD) in hypothalamic homogenates (assayed in vitro) exhibited a parallel small decline; its activity in brain homogenates, however, was not significantly changed. Administration of pyridoxine·HCl (200 mg/kg/day for 3 days) in addition to carbidopa blocked the fall in hypothalamic AAAD activity. Pyridoxine administration did not affect the inhibition of peripheral AAAD by carbidopa in vivo; it failed to interfere with carbidopa’s blockade of decarboxylation of exogenous L-dopa (100 mg/kg, given intraperitoneally 1 hr before sacrifice). These findings suggest that large doses of carbidopa can, by depleting tissues of PLP, cause potentially undesirable nonspecific changes in pyridoxine-dependent enzymes. However, the coadministration of pyridoxine with carbidopa can maintain tissue PLP levels and protect against such enzyme changes.

Because carbidopa selectively inhibits the enzyme aromatic L-amino acid decarboxylase (AAAD) in peripheral tissues,1 it increases the proportions of each dose of dopa that reaches the brain; this makes it a useful adjunct in the treatment of Parkinson’s disease.2 Carbidopa is capable of suppressing the decarboxylation of endogenous3 as well as exogenous4·5 dopa; the resulting inhibition of norepinephrine synthesis within sympathetic nerve terminals3 may underlie carbidopa’s ability to potentiate the antihypertensive actions of a number of chemically unrelated drugs in spontaneously hypertensive rats.6

Carbidopa is a hydrazine derivative of the amino acid L-dopa. It has been suggested7·8 that its hydrazine group might bind chemically to pyridoxal-5’-phosphate (PLP) to form a Schiff base (Fig. 1), as dopa and other amino acids and amines do.9·10 Such binding between carbidopa and PLP has been demonstrated in vitro;11 the second-order rate constant for formation of the Schiff base was found to be 20 times greater for carbidopa than for dopa. The admin-